Bromfenac

Bromfenac
Clinical data
Trade names	Bromday, Prolensa (US), Yellox (EU)
AHFS/Drugs.com	Monograph
MedlinePlus	a611018
License data	US DailyMed: Bromfenac;
Routes of; administration	Eye drops
ATC code	S01BC11 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Protein binding	99.8%
Metabolism	CYP2C9
Metabolites	Lactam, others
Elimination half-life	1.4 hours in aqueous humour
Excretion	82% urine, 13% faeces
Identifiers
	IUPAC name 2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid;
CAS Number	91714-94-2 ;
PubChem CID	60726;
IUPHAR/BPS	7131;
DrugBank	DB00963 ;
ChemSpider	54730 ;
UNII	864P0921DW;
KEGG	D07541 ; as salt: D03163 ;
ChEBI	CHEBI:240107 ;
ChEMBL	ChEMBL1077 ;
CompTox Dashboard (EPA)	DTXSID7040655 ;
Chemical and physical data
Formula	C15H12BrNO3
Molar mass	334.169 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	284 to 286 °C (543 to 547 °F) (bromfenac sodium·1.5H2O)
	SMILES O=C(c1ccc(Br)cc1)c2cccc(c2N)CC(=O)O;
	InChI InChI=1S/C15H12BrNO3/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19/h1-7H,8,17H2,(H,18,19) ; Key:ZBPLOVFIXSTCRZ-UHFFFAOYSA-N ;
	(verify)

Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) marketed in the US as an ophthalmic solution (brand names Prolensa and Bromday, prior formulation brand name Xibrom, which has since been discontinued) by ISTA Pharmaceuticals for short-term, local use. Prolensa and Bromday are the once-daily formulation of bromfenac, while Xibrom was approved for twice-daily administration. In the European Union, the brand name is Yellox. Bromfenac is indicated for the treatment of ocular inflammation and pain after cataract surgery.